Challenge to supplementary protection on Takeda ADHD drug falls flat in UK
By Melissa Ritti ( September 25, 2026, 21:16 GMT | Insight) -- A supplementary protection certificate which provided protection after patent expiry for the active ingredient in Takeda’s ADHD drug Elvanse in the UK was deemed valid there on Thursday. The ruling marks a blow to two generic drugmakers and a break with the German Federal Patent Court in Munich.A UK court upheld Takeda’s supplementary protection certificate for Elvanse on Thursday, rejecting reasoning a German court used to invalidate the corresponding German certificate....
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.